GMED
insider transactionsGLOBUS MEDICAL INC — buys & sells by directors, officers and 10% owners A shareholder owning more than 10% of the company. Must report trades, but usually a weaker signal than an officer or director. (SEC Form 4).
Net shares · 365d
-60.6K
0 buy · 60.6K sell
Net value · 365d
-$5.4M
$0 in · $5.4M out
Sentiment · 365d
Net selling
0% buying · 100% selling
Open-market trades · 365d
5
0 buy · 60.6K sell
Net buy / sell volume
Not enough data to chart yet.
Tap or hover the chart for daily net volume. Green = net buying, red = net selling.
All transactions
-
Exercise·M
Director
$0
25.0K sh
Own New
-
Sell·S
Director
$2.0M
25.0K sh · $80.76
Own -5%
-
Exercise·M
Director
$656.8K
25.0K sh · $26.27
Own +5%
-
Exercise·M
Director
$0
25.0K sh
Own New
-
Exercise·M
Director
$656.8K
25.0K sh · $26.27
Own +163%
-
Exercise·M
EVP, GC, Corporate Secretary · 10b5-1
$0
20.0K sh
Own New
-
Sell·S
EVP, GC, Corporate Secretary · 10b5-1
$1.9M
20.0K sh · $94.50
Own -100%
-
Exercise·M
EVP, GC, Corporate Secretary · 10b5-1
$871.6K
20.0K sh · $43.58
Own New
-
Exercise·M
EVP, GC, Corporate Secretary · 10b5-1
$0
10.0K sh
Own New
-
Sell·S
EVP, GC, Corporate Secretary · 10b5-1
$876.7K
10.0K sh · $87.67
Own -100%
-
Exercise·M
EVP, GC, Corporate Secretary · 10b5-1
$456.4K
10.0K sh · $45.64
Own New
-
Grant·A
Director
$0
15.0K sh
Own New
-
Grant·A
Keith W Pfeil KEY
President, CEO
$0
100.0K sh
Own New
-
Grant·A
Kyle Kline KEY
Senior Vice President, CFO
$0
30.0K sh
Own New
-
Grant·A
David C Paul KEY
Executive Chairman
$0
100.0K sh
Own New
-
Grant·A
Director
$0
15.0K sh
Own New
-
Grant·A
Director
$0
15.0K sh
Own New
-
Grant·A
Director
$0
15.0K sh
Own New
-
Grant·A
Director
$0
15.0K sh
Own New
-
Grant·A
Director
$0
15.0K sh
Own New
-
Grant·A
EVP, GC, Corporate Secretary
$0
40.0K sh
Own New
-
Grant·A
Director
$0
15.0K sh
Own New
-
Grant·A
Director
$0
15.0K sh
Own New
-
Exercise·M
Kyle Kline KEY
Senior Vice President, CFO · 10b5-1
$0
3.6K sh
Own +1152%
-
Sell·S
Kyle Kline KEY
Senior Vice President, CFO · 10b5-1
$363.4K
3.6K sh · $101.10
Own -100%
-
Exercise·M
Kyle Kline KEY
Senior Vice President, CFO · 10b5-1
$186.4K
3.6K sh · $51.87
Own New
-
Sell·S
Director · 10b5-1
$202.2K
2.0K sh · $101.10
Own -16%
-
Exercise·M
Kyle Kline KEY
Senior Vice President, CFO
$0
4.9K sh
Own New
| Date▾ | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Jun 5, 2026 | David D Davidar | Exercise M | 25.0K | $0 |
| Jun 5, 2026 | David D Davidar | Sell S | 25.0K | $2.0M |
| Jun 5, 2026 | David D Davidar | Exercise M | 25.0K | $656.8K |
| Jun 4, 2026 | Ann D Rhoads | Exercise M | 25.0K | $0 |
| Jun 4, 2026 | Ann D Rhoads | Exercise M | 25.0K | $656.8K |
| Feb 25, 2026 | Kelly Huller 10b5-1 | Exercise M | 20.0K | $0 |
| Feb 25, 2026 | Kelly Huller 10b5-1 | Sell S | 20.0K | $1.9M |
| Feb 25, 2026 | Kelly Huller 10b5-1 | Exercise M | 20.0K | $871.6K |
| Feb 12, 2026 | Kelly Huller 10b5-1 | Exercise M | 10.0K | $0 |
| Feb 12, 2026 | Kelly Huller 10b5-1 | Sell S | 10.0K | $876.7K |
| Feb 12, 2026 | Kelly Huller 10b5-1 | Exercise M | 10.0K | $456.4K |
| Jan 21, 2026 | Leslie V Norwalk | Grant A | 15.0K | $0 |
| Jan 21, 2026 | Keith W Pfeil KEY | Grant A | 100.0K | $0 |
| Jan 21, 2026 | Kyle Kline KEY | Grant A | 30.0K | $0 |
| Jan 21, 2026 | David C Paul KEY | Grant A | 100.0K | $0 |
| Jan 21, 2026 | Dan Lemaitre | Grant A | 15.0K | $0 |
| Jan 21, 2026 | Ann D Rhoads | Grant A | 15.0K | $0 |
| Jan 21, 2026 | James R Tobin | Grant A | 15.0K | $0 |
| Jan 21, 2026 | Stephen T Zarrilli | Grant A | 15.0K | $0 |
| Jan 21, 2026 | Dan Wolterman | Grant A | 15.0K | $0 |
| Jan 21, 2026 | Kelly Huller | Grant A | 40.0K | $0 |
| Jan 21, 2026 | Robert Andrew Douglas | Grant A | 15.0K | $0 |
| Jan 21, 2026 | David D Davidar | Grant A | 15.0K | $0 |
| Jan 8, 2026 | Kyle Kline KEY 10b5-1 | Exercise M | 3.6K | $0 |
| Jan 8, 2026 | Kyle Kline KEY 10b5-1 | Sell S | 3.6K | $363.4K |
| Jan 8, 2026 | Kyle Kline KEY 10b5-1 | Exercise M | 3.6K | $186.4K |
| Jan 8, 2026 | Leslie V Norwalk 10b5-1 | Sell S | 2.0K | $202.2K |
| Dec 1, 2025 | Kyle Kline KEY | Exercise M | 4.9K | $0 |
About GMED insider trading
This page tracks insider transactions for GLOBUS MEDICAL INC (GMED) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.